Evaluation of Cost-Effective Strategies for Rabies Post-Exposure Vaccination in Low-Income Countries by Hampson, Katie et al.
Evaluation of Cost-Effective Strategies for Rabies Post-
Exposure Vaccination in Low-Income Countries
Katie Hampson
1*, Sarah Cleaveland
1, Deborah Briggs
2
1Boyd Orr Centre for Population and Ecosystem Health, Institute for Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United
Kingdom, 2Global Alliance for Rabies Control, Manhattan, Kansas, United States of America
Abstract
Background: Prompt post-exposure prophylaxis (PEP) is essential in preventing the fatal onset of disease in persons
exposed to rabies. Unfortunately, life-saving rabies vaccines and biologicals are often neither accessible nor affordable,
particularly to the poorest sectors of society who are most at risk and upon whom the largest burden of rabies falls.
Increasing accessibility, reducing costs and preventing delays in delivery of PEP should therefore be prioritized.
Methodology/Principal Findings: We analyzed different PEP vaccination regimens and evaluated their relative costs and
benefits to bite victims and healthcare providers. We found PEP vaccination to be an extremely cost-effective intervention
(from $200 to less than $60/death averted). Switching from intramuscular (IM) administration of PEP to equally efficacious
intradermal (ID) regimens was shown to result in significant savings in the volume of vaccine required to treat the same
number of patients, which could mitigate vaccine shortages, and would dramatically reduce the costs of implementing PEP.
We present financing mechanisms that would make PEP more affordable and accessible, could help subsidize the cost for
those most in need, and could even support new and existing rabies control and prevention programs.
Conclusions/Significance: We conclude that a universal switch to ID delivery would improve the affordability and
accessibility of PEP for bite victims, leading to a likely reduction in human rabies deaths, as well as being economical for
healthcare providers.
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Introduction
Rabies is invariably fatal once clinical signs appear but can be
readily prevented after exposure with prompt and appropriate
post-exposure prophylaxis (PEP) [1]. PEP is therefore the most
critical life-saving intervention essential for the prevention of rabies
in humans after exposure [2]. In reality, most of the estimated 7
million people exposed to rabies each year live in resource poor
countries where life-saving rabies vaccines are not always available
or easily affordable [3,4,5,6]. This stark situation contributes to the
fact that almost all of the estimated 55,000 annual human rabies
deaths occur in Africa and Asia where the virus circulates
endemically in domestic dog populations [7].
The WHO-recommended PEP protocol includes immediate
wound washing, expeditious administration of rabies vaccine, and
for severe categories of exposure, infiltration of purified rabies
immunoglobulin (RIG) in and around the wound [8]. RIG is
rarely administered in low-income countries because it is
expensive (from USD$25 to over USD$200 depending on whether
it is of equine or human origin)[7,9] and in short supply (see the
following examples: [3,4,5,10]). Therefore, it is usually only post-
exposure vaccination (without RIG) that is administered to protect
a bite victim from succumbing to rabies [3]. Several factors affect
the likelihood of promptly obtaining and completing PEP
vaccination. Vaccine vials cost from USD$7–20 in most low-
income countries and multiple vials are required per patient
contingent upon the PEP regimen used. In some countries,
governments provide vaccine free-of-charge or subsidize its cost,
but budgets allocated for this are often insufficient, resulting in
shortages or leaving only a few centres with a reliable supply.
Alternatively, victims pay for vaccine, but charges are often
prohibitive [3]. Costs of travel and or accommodation accumulate
according to the number of clinic visits that a patient and, in many
cases, an accompanying family member, makes to complete PEP.
These considerable indirect costs [7] are affected by vaccine
availability, and rise during shortages when patients and families
are forced to travel further (often to multiple clinics), wasting time
and money [3]. Delays caused by shortages also reduce
compliance. All too often victims fail to promptly obtain or
complete PEP, which in the worst cases results in rabies deaths
[3,4,5].
Following WHO approval of intradermal (ID) administration
of PEP vaccines [11], there has been significant discussion of
the value of ID versus intramuscular (IM) delivery
[2,12,13,14,15,16,17]. The main argument is that ID vaccination
is more economical because smaller volumes of vaccine can be
www.plosntds.org 1 March 2011 | Volume 5 | Issue 3 | e982used to elicit an equivalent immune response (0.1 mL for each ID
injection versus one 0.5 or 1 mL vial for each IM injection). The
caveat of ID regimens is that vaccine remaining in partially used
vials must be discarded within 6 to 8 hours to minimize risks of
bacterial contamination (current vaccines do not contain preser-
vatives) [2,18], which may be perceived as waste. Moreover, vial
sharing amongst patients may lead to practical difficulties in health
provider budgeting. All WHO-recommended PEP regimens for
WHO pre-qualified vaccines are safe, immunogenic, and
efficacious. Thus policy should aim to prevent failures in PEP
delivery by preventing vaccine shortages, reducing costs for victims
and healthcare providers and promoting patient compliance to
ensure PEP efficacy. The variety of WHO-recommended PEP
regimens allows flexibility, but can lead to confusion regarding
which regimen best meets the needs for a specific setting.
Additionally, new regimens are continually being developed that
require evaluation prior to implementation. Here, we provide a
framework for comparing cost-effectiveness of different PEP
regimens (including existing approved regimens and new candi-
dates subject to approval) from the perspective of both healthcare
providers and bite victims under a range of scenarios (from low to
high throughput clinics) and under realistic constraints (poor
patient compliance and some vaccine wastage). We discuss the
implications for PEP affordability, availability and accessibility and
offer recommendations for policy formulation and vaccine
research.
Methods
We developed a simulation framework for evaluating vaccine
use under different PEP regimens. We compared different
vaccination regimens (detailed in Table 1) that are currently
approved by WHO and the Advisory Committee on Immuniza-
tion Practices (ACIP), together with two additional candidate
regimens (the 4-site and 1-week ID PEP regimens), that have
recently undergone clinical trials and could potentially be used in
future conditional upon review and approval by WHO. The
algorithm for our simulations is shown in Figure 1 with an
example scenario.
Cost data
We used cost data associated with rabies reported from previous
studies (Table 2). These include direct (medical) costs correspond-
ing to rabies vaccines and their administration and indirect (non-
Author Summary
Rapid delivery of post-exposure vaccination is essential for
preventing the fatal onset of rabies in persons bitten by
rabid animals. But for communities most at risk of
exposure to rabies (in resource poor countries where
domestic dog rabies is still common), post-exposure
vaccines are often not affordable and are only available
in limited quantities. Several safe and effective regimens
for delivery of these vaccines are recommended by WHO,
but these are inconsistently implemented and there are no
clear recommendations as to which is the best regimen for
specific settings. We developed a framework for compar-
ing the cost-effectiveness of different vaccination regi-
mens, including existing approved regimens and new
candidates subject to approval, in terms of costs per death
averted. We demonstrate that post-exposure vaccination is
an extremely cost-effective public health intervention and
that changing delivery from intramuscular to intradermal
vaccination has considerable benefits. Large savings in the
volume of vaccine required to treat the same number of
patients could potentially both mitigate vaccine shortages
and reduce delays in delivery, enabling wider vaccine
distribution, and thus improving the accessibility and
affordability of these life-saving vaccines. We also present
financing mechanisms that could help subsidize the cost
for those most in need, and even support new and existing
rabies control and prevention programs, without compro-
mising existing healthcare budgets.
Table 1. Attributes of rabies post-exposure vaccination regimens.
Regimen
Name
Clinic
visits
required
Schedule of
visits (day)
Injections
per visit
Vials opened/
accessed per
PEP course
Volume of vaccine
used for 1 course
of PEP (mL)**
Route of
administration
Approval
status References
Essen
5-dose
5 0,3,7,14,28 1,1,1,1,1 5 5 (2.5)* IM WHO 1992- [11]
Essen
4-dose
4 0,3 7,14 1,1,1,1 4 4 (2)* IM ACIP 2009- [21]
Zagreb 3 0,7,21 2,1,1 4 4 (2)* IM WHO 1992- [34]
Thai Red
Cross ID
5 0,3,7,28,90 2,2,2,1,1 5 0.8 ID WHO 1992 [34]
Updated
Thai Red
Cross ID
4 0,3,7,28 2,2,2,2 4 0.8 ID WHO 2005- [32,35]
4-site ID 4 0,7,28,90 4,2,1,1 4 0.8-0.9 ID Not yet approved [36]
1-week ID 3 0,3,7 4,4,4 3 1.2–1.5 ID Not yet approved [37]
We do not include the rarely used 8-site ID regimen [32] as it was recently recommended that this be removed from the list of WHO-approved ID regimens to simplify
and facilitate the use of ID PEP [33]. We did not include the Thai Red Cross (TRC) regimen in analyses, because the updated TRC is always preferable requiring 4 rather
than 5 clinic visits, thus entailing fewer indirect costs.
ID=intradermal, IM=intermuscular.
ACIP=Advisory Committee on Immunization Practices, USA.
*Calculated assuming 0.5 mL vials are used. **For ID regimens that use 0.4 mL or 0.8 mL of vaccine in a single hospital visit, we assume that in many cases a whole vial
of vaccine will be divided between injection sites.
doi:10.1371/journal.pntd.0000982.t001
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income while receiving PEP. We assume that the time taken to
vaccinate a patient is equivalent for both ID and IM administra-
tion and we did not include costs of RIG because most bite victims
in Africa and Asia do not receive RIG [3,4,5].
Definitions
We explored vaccine use according to different model inputs
that are detailed in Table 3 and defined as follows:
Clinic throughput. The number of bite patients presenting
to a clinic for the first time in need of PEP. In contrast, the overall
number of patients presenting to a clinic depends on the PEP
regimen in use, its schedule requirements (Table 1) and the degree
to which patients comply.
Vial size. Most rabies vaccines are sold in 0.5 mL or 1 mL
vials, at equal cost, which affects the number of patients that can
share the vial for ID vaccinations.
Vaccine wastage. Opened vials must be used within 6–
8 hours and in practice there will always be some wastage of
vaccine. For regimens that use almost a complete vial (460.1 mL
injections from a 0.5 mL vial) during a clinic visit (4-site and 1-
week ID, Table 1), practitioners may opt to divide a single 0.5 mL
vial to provide the four injections or a 1 mL vial to provide eight
injections. We therefore compared scenarios whereby different
numbers of 0.1 mL injections can be obtained from a vial
(according to vial size, see Table 3).
Patient compliance. The probability of a bite patient
returning to a clinic for subsequent PEP vaccination(s). Poor
compliance has consequences for vaccine use, vial sharing and
PEP efficacy (see below). We investigate compliance in terms of the
probability of returning for each visit rather than variability in the
date of return. We assume patient compliance is affected by the
cost of obtaining PEP and explore the implications of this
relationship.
Vaccination efficacy. For the purposes of these comparative
analyses, we assumed 100% efficacy of complete PEP vaccination
in preventing rabies cases for all regimens. In the absence of PEP
vaccination we assume that just under 20% of victims of bites by
rabid animals develop rabies and that all clinical cases of human
rabies result in death [19]. Incomplete PEP vaccination is less
effective and almost 10% of human rabies cases reported from
study in India had received incomplete PEP vaccination with
CCVs [20]. However we were unable to find data on the impact of
incomplete PEP vaccination on the likelihood of rabies onset.
Rabies virus neutralization antibody titres increase following
primary vaccination, generally peaking between days 14–28
[13,21,22]. Therefore for scenarios with less than 100% patient
compliance we assume additive protection with each consecutive
vaccination and explore a range of efficacies (Table 3).
We ran 1000 realisations (see Figure 1 example) for each
scenario to capture variation in dates of patient presentation and
consequences for vial sharing.
Outcomes
We analyzed outcomes in terms of savings in vaccine use,
human rabies cases averted and incremental cost-effectiveness
ratios. We evaluated incremental cost-effectiveness ratios (ICER)
in terms of dollars per rabies death averted: costsPEP/
(EffectivenessPEP-EffectivenessNo PEP), where subscripts refer to
whether or not PEP vaccination was administered. We calculated
Figure 1. Simulation framework for determining vaccine use under different PEP regimens and model inputs. Framework for exploring
different model inputs (detailed in Table 3) including degree of patient compliance, types of vaccine vials and levels of vaccine waste.
doi:10.1371/journal.pntd.0000982.g001
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included only direct medical costs. We also modify this calculation
of cost-effectiveness under poor compliance and according to
hypothesized protective efficacy of incomplete vaccination
(Table 3).
We compiled data on clinic throughputs in different settings and
calculated the annual costs of PEP vaccination using different
regimens for these settings. In practice, many clinics operate on a
cost-recovery basis and charge for PEP. However, the number of
new and returning animal-bite patients expected at a clinic on a
daily basis cannot be precisely predicted, making it difficult to
determine appropriate charges for ID administration. We
compared four pricing strategies: 1) charging patients per injection
according to the amount of vaccine used; 2) charging patients per
injection at rates that are marginally higher than the price of the
amount of vaccine used (illustrated with patients paying per
injection at a rate that is 25% or 30% of vial costs); 3) charging
patients a set price on their first visit (illustrated with a fee
equivalent to 1.5 vials), but providing all subsequent doses without
payment; 4) charging patients the price of one vial for each of their
first and second hospital visits, but providing vaccine for free on
subsequent visits. For all the strategies we assume that patients pay
Table 2. Costs associated with PEP vaccination.
Cost type Parameter Estimate (USD) Reference
Medical Material costs per injection (needles, syringes, swabs) $0.1 [7], Global
$0.4 [38], India
Overhead costs per clinic visit (staff salaries,
administration)
$0.5 [39], Global
$1.2 [38], India
Vaccine costs per vial $8.75–11.5 [29], Thailand
$7.5 http://www.msd.or.tz/ Tanzania
$8–20 M. Sambo, pers com, Tanzania,
$11 J. Girardi, pers com, Indonesia
$18 [40], China
$7–18 [41], South-East Asia
$10 [7], WHO procurement services
$7–9 D. Xuyen, pers com, Vietnam
$6.6 [38], India
Non-medical Transport, accommodation and income loss costs
per clinic visit
$2.9–5.5 [7], Africa, Asia
$7–14 [42], Tanzania
Costs vary within and between countries. For the purpose of comparison, in our simulations we used the values that are emboldened, but absolute cost-effectiveness
will depend on specific settings. Note that for analyses of costs from the patient perspective, we explore the full range of indirect costs.
doi:10.1371/journal.pntd.0000982.t002
Table 3. Model inputs and sensitivity analyses conducted during simulations.
Model inputs Description Range
Clinic throughput Average number of new animal-bite patients
presenting at a clinic each month
1–1000 new patients/month
Regimen Intramuscular or intradermal regimen
used for all animal bite patients
Essen 4-dose (IM), Zagreb (IM)
Updated-TRC (ID), 4-site (ID), 1-week (ID)
Vial type Vial size stocked by clinic 0.5 mL, 1 mL
Compliance Probability of completing each
subsequent visit for PEP vaccination
100% (complete compliance), 50% (poor compliance). In analyses we assume that
increased costs reduce compliance, and specifically that there is complete
compliance when a full course of PEP costs bite-victims $10 or less, but for every $1
increase in cost, compliance is reduced by 0.05%.
Wastage The number of 0.1 mL injections that can
be obtained from a vial
All opened vials must be discarded at the end of the day. Wastage: 4 injections from
a 0.5 mL vial, and 8 from a 1 mL vial. No wastage: 5 injections from a 0.5 mL vial,
and 10 from a 1 mL vial
Vaccination efficacy Effectiveness of each subsequent vaccination visit in
preventing the onset of rabies
We explored hypothetical additive protective efficacy of each vaccination day on
the cost-effectiveness of regimens (from 0–100%). E.g. If each vaccination day
provides 90% protection, with the updated TRC regimen, 90% of victims will be
protected on d0, 99% on d7 and 99.9% on d14 and 100% on d28, whereas using the
1-week regimen 100% would be protected on d7.
doi:10.1371/journal.pntd.0000982.t003
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is equivalent to the price of overhead for a clinic visit in addition to
the vaccination costs described above. We explored implications
for cost recuperation (based on costs of PEP delivery shown in
Table 2) by estimating annual savings of the different pricing
strategies dependent upon throughput and the regimen in use. We
present the net gains under these pricing strategies for the updated
TRC regimen (the only currently WHO approved ID regimen) for
clinics for which throughput data was compiled.
We compare the costs of PEP for bite-victims, depending upon
the pricing strategies described above and including the provision
of PEP free-of-charge and under different assumptions about
indirect costs (based on the range of indirect costs in Table 2).
Specifically we assume that bite victims travel further to reach a
clinic in rural rather than urban settings and incur correspondingly
higher costs. We also calculate the likely risks for patients of poor
PEP compliance according to assumptions about vaccine efficacy
(Table 2) and explore how costs may affect compliance with PEP
regimens and implications for the risk of developing rabies.
All analyses were performed using the statistical programming
language R. Scripts implementing our simulations are available
upon request.
Results
For IM vaccination, both the reduced 4-dose Essen and the
Zagreb regimens are more economical than the 5-dose Essen
because they use only 4 vaccine vials in comparison to 5 vials for
the 5-dose schedule, i.e. 80% of the total volume of vaccine
(Table 1). All ID regimens use less vaccine than IM regimens and
are cost less per rabies death averted (Figure 2). Clinic throughput
generally increases the cost-effectiveness of ID vaccination, with
high throughput clinics most cost-effective and low throughput
clinics least cost-effective. The only exception to this is the
situation where some wastage is assumed and 0.5 mL vials are
used, in which case the 1-week ID regimen does not increase in
cost-effectiveness with throughput (Figure S1), but is still
considerably more cost-effective than IM regimens.
The updated TRC and the 4-site ID regimens were the most
cost-effective in high throughput settings (between $100 and $55
per life saved depending on throughput and vial size). While in
very low throughput clinics, the 1-week ID regimen was the most
cost-effective ($160–150 per life saved, Figure 1). In high
throughput clinics the updated TRC and 4-site ID regimens use
just 40% of the volume of vaccine in comparison to preferred IM
regimens (Essen 4-dose and Zagreb) when 0.5 mL vials are used
and 20% of the volume when 1 mL vials are used (Table 1,
Figure 1). The cost-effectiveness of all ID regimens increases
considerably when 1 mL vials are used instead of 0.5 mL vials
(Figure 1). The estimated costs of PEP vaccination to health
providers are shown for different regimens in Table 4 for a variety
of throughput settings and illustrate how provision of PEP using
ID regimens is considerably more economic than provision of PEP
using IM regimens.
When health providers charge for PEP vaccination according to
the strategies described, substantial costs are recovered when using
ID regimens and in most cases savings are made. The extent of
savings and how these vary with clinic throughput for different ID
regimens are shown in Figure 3. Using 1 mL vials rather than
0.5 mL vials increases savings for all pricing strategies. Charging
patients for exactly the amount of vaccine administered using the
ID route results in a net loss for healthcare providers except in
Figure 2. Cost of vaccination per rabies death averted for different PEP regimens according to clinic throughput. Costs for IM
administered vaccinations (the Zagreb regimen and the Essen 4-dose reduced regimen are exactly equivalent and shown in black) and ID
administered vaccinations (the updated TRC regimen is shown in blue, the 4-site in red, and the 1-week in grey) per rabies death averted is plotted
against clinic throughput (the number of new animal bite patients presenting for PEP vaccination each month). Shading represents 99% confidence
intervals resulting from variation in patient arrival dates and the effects on vial sharing. Dashed lines highlight optimal vaccine use in high throughput
clinics. Panel A is based on 0.5 mL vials and panel B on 1 mL vials. Here, we assume that vaccine is perfectly delivered without any wastage (5
complete 0.1 mL injections from a 0.5 mL vial, and 10 complete 0.1 mL injections from a 1 mL vial), but we show the reductions in efficiency
assuming some wastage in Figure S1. Note the x-axis is plotted on a log scale.
doi:10.1371/journal.pntd.0000982.g002
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www.plosntds.org 6 March 2011 | Volume 5 | Issue 3 | e982high throughput clinics. Charging patients per ID injection at rates
slightly greater than the price of the vaccine used results in net
savings in most locations (Figure 3 shows savings for charging $2.5
or $3/injection assuming vials cost $10). Other strategies such as
charging higher rates but for the primary presentation only, or for
primary and secondary presentations only, also result in significant
savings for high throughput clinics and losses occur only in very
low throughput clinics when 1 mL vials are used. For example,
when using 1 mL vials, charging the price of a vial for each of the
first 2 presentations, results in savings in clinics that receive over 15
new patients per month with all the ID regimens, whereas losses
are always incurred when using 0.5 mL vials in lower throughput
clinics (Figure 3). Similar savings are made in high throughput
clinics charging a fixed price for a full PEP course when 1 mL vials
are used (illustrated by a $15 set rate, assuming a vial costs $10, in
Figure 3), however, charging $15 for a full ID course (all regimens)
is not sufficient to recuperate costs when using 0.5 mL vials.
Extrapolations assuming use of the $15 full course of the updated
TRC regimen with 1 mL vials (the only ID regimen currently
recommended by WHO) suggest that even in countries with
mainly low throughput clinics (e.g. Tanzania), savings recuperated
from urban centres would ensure sustainability, and in the highest
throughput settings annual savings could exceed $100,000 in a
single clinic (Table 4).
Where PEP vaccination is provided free-of-charge, the Zagreb
IM and the recently proposed 1-week ID regimens are most
preferable for patients, who incur only indirect costs (Table 5).
This is because only 3 hospital visits are required as compared to
the Essen IM and the updated TRC and 4-site ID regimens, which
all require 4 visits (Table 1). When patients are required to pay for
PEP vaccination, the most preferable regimen for bite victims
varies depending on pricing strategies and relative travel costs
(Table 5). However, in terms of price, ID regimens are always
preferable over IM regimens. When travel costs are low and PEP
is charged per injection, the updated TRC and the 4-site ID
regimens are preferable. The 1-week ID regimen is preferable
when travel costs are high, and particularly when flat rates are
charged for the full PEP course, rather than per injection (Table 5).
We assume that high costs reduce patient compliance, which in
turn reduces the effectiveness of PEP in preventing rabies and thus
the cost-effectiveness of PEP. Specifically, we assume 100%
compliance when patients pay $10 or less for PEP, and that for
every dollar increase there is a 0.05% reduction in compliance
(Table 3), thus the most expensive regimen ($98.4 per course for
the Essen 4-dose IM for patients with high travel costs, Table 5),
has only 42.8% compliance. The cost per rabies death averted
decreases as the efficacy of the regimen increases, and therefore
cost-effectiveness increases and a greater proportion of preventable
deaths are averted (Figure 4A & B). Cost-effectiveness is lowest at
low levels of compliance. The proportion of deaths prevented also
increases with vaccine efficacy (Figure 4B). At low levels of vaccine
efficacy, regimens that require 3 clinic visits (Zagreb, 4-site ID, 1
week ID) prevent a greater percentage of deaths than regimens
that require 4 clinic visits (Essen 4-dose, updated TRC). Overall,
the risk of death increases with the costs of PEP as patients become
less likely to comply with regimens (Figure 4C). For all pricing
strategies that we present, patients who live further from clinics
have reduced compliance and heightened risks. When PEP
vaccination is free of charge, risks are minimized, and risks are
maximized when charging for IM regimens (Figure 4C).
Figure 3. Clinic monthly savings and losses from ID administration of PEP under different pricing mechanisms. A & E) patients are
charged $2.5 per injection (25% of vial costs assuming a single vial costs $10) as well as a consultation fee and materials costs (see Table 4 for the
costs from the perspective of the bite victim). B & F) patients are charged $3 per injection (30% of vial costs) as well as a consultation fee and
materials costs. C & G) patients are charged a flat rate of $15 for the full PEP course (the cost of 1.5 vials) as well as a consultation fee and materials
costs. D & H) patients are charged a flat rate of $20 for the full PEP course ($10 for each of the first two clinic visits, equivalent to two vials) as well as a
consultation fee and materials costs. A, B, C, & D) compare regimens across a range of patient throughputs (from very low to very high, 1–1000
patients per month). E, F, G & H) are a closer examination of costs in low throughput clinics (1–50 patients per month). Blue lines indicate the updated
TRC ID, red lines indicate the 4-site ID and gray lines indicate the 1-week ID regimens respectively, with solid lines corresponding to 0.5 mL vials and
dashed lines corresponding to 1 mL vials. The pricing strategies shown would all result in substantial losses for IM delivered PEP vaccination (not
shown).
doi:10.1371/journal.pntd.0000982.g003
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Rabies post-exposure vaccination is essential for preventing this
fatal disease but can be out of the financial reach of many bite
victims. Vaccine shortages are common in developing countries
and due to limited availability bite victims often need to travel long
distances to obtain vaccine. Thus, patients often incur substantial
costs and face dangerous delays in securing PEP and avoidable
human rabies deaths occur as a direct result of poor access to
affordable PEP [3,4,5]. We examined the costs of IM versus ID
administration of PEP vaccine in different settings and under
realistic constraints such as poor compliance. We demonstrate that
ID delivery of PEP is considerably more cost-effective than IM
delivery in terms of averting rabies cases and saving lives. Clinic
throughput affects the capacity for vial sharing, and therefore the
cost-effectiveness of ID administration relative to IM. As
throughput increases, ID regimens become increasingly cost-
effective, using up to 80% less vaccine (Figure 1). Yet, even clinics
with relatively low throughput (,10 new patients/month) would
reduce vial use by 25% by switching from IM to ID administration
Figure 4. Effects of compliance on PEP effectiveness in preventing rabies and cost-effectiveness per death averted. A) Additive
protective efficacy of PEP (defined in Table 3) given 50% compliance is plotted against cost-effectiveness per rabies death averted, calculated from
direct medical costs (Table 2). The different regimens are indicated as follows: reduced 4-dose Essen IM regimen in thick black, Zabreb IM in thin
black, updated TRC ID in blue, 4-site ID in red and 1 week ID in gray. The dashed lines correspond to complete compliance. Here we assume use of
0.5 mL vials and clinic throughput of 100 new bite patients per month. Assuming use of 1 mL vials results are qualitatively similar but more cost-
effective. B) Additive protective efficacy of PEP regimens (Table 3) is plotted against the percentage of rabies deaths averted at high (100%, dotted
lines), moderate (75%, dashed lines) and poor (50%, solid lines) levels of compliance. Thick lines correspond to regimens requiring 4 clinic visits
(reduced Essen 4-dose IM, updated TRC ID) and thin lines correspond to regimens requiring 3 clinic visits (Zagreb IM, 4-site ID, 1-week ID). C) The
costs of PEP regimens for bite victims according to different pricing strategies (Table 5) are plotted against the risk of developing rabies assuming
75% additive protective efficacy for each PEP visit and assuming that patient compliance is affected by PEP costs (as described in Table 3).
doi:10.1371/journal.pntd.0000982.g004
Table 5. Costs of PEP vaccination regimens from the bite-victim perspective.
Travel costs only
(USD$): $2.5 per injection: $3 per injection: $15 full course: $10 for 1st and 2nd visits:
Regimen Near
1 Far
2 Near
1 Far
2 Near
1 Far
2 Near
1 Far
2 Near
1 Far
2
Updated TRC ID 11.6 56 34.4 78.8 38.4 82.8 29.4** 73.8** 34.4 78.8
4-site ID 11.6 56 34.4 78.8 38.4 82.8 29.4** 73.8** 34.4 78.8
1-week ID 8.7 42 41.4 74.7 47.4 80.7 26.4** 59.7** 31.4** 64.7**
Essen 4-dose* 11.6 56 54* 98.4* 54* 98.4* 54* 98.4* 54* 98.4*
Zagreb* 8.7 42 50.6* 83.9* 50.6* 83.9* 50.6* 83.9* 50.6* 83.9*
Costs were calculated based on whether PEP vaccination is provided free-of-charge, or according to different pricing strategies. The most affordable regimens are
emboldened for each strategy. We assume that for each clinic visit patients pay a consultation fee (that is equivalent to the price of overhead for a clinic visit) and the
costs of materials for injections (Table 2).
1Low indirect costs are assumed to be $2.9/visit (best case scenario in Table 2), corresponding to patients from urban areas that only need to travel relatively short
distances to obtain PEP.
2High indirect costs are assumed to be $14/visit (worst case scenario in Table 2), which corresponds to patients from rural areas, that have to travel long-distances to a
hospital and may need to stay overnight whilst seeking PEP.
*For IM regimens, when patients pay for PEP vaccination we assume they pay $10/vial (Table 2).
**When using 0.5 mL vials, charging $15 for a full course does not recuperate costs for any ID regimen and charging $10 for each of the first two clinic visits does not
recuperate costs for the 1-week ID regimen (see Figure 3).
doi:10.1371/journal.pntd.0000982.t005
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vaccine shortages and enable wider vaccine distribution, both
increasing the number of patients that can be treated and the
overall accessibility of PEP. Concurrent changes in PEP costs to
patients could also improve affordability, while providing incen-
tives for compliance without compromising existing health
budgets. These issues should be considered in the design of PEP
policy because they could reduce the burden of rabies by
increasing the availability of vaccines for the rural poor who bear
the brunt of rabies in most developing countries.
Our principal finding that ID administration of PEP is more
cost-effective than IM administration and reduces the amount of
vaccine used is important given the frequency with which PEP
vaccine shortages occur at clinics in many developing countries.
Savings in vaccine use are substantially larger when using
equivalently priced 1 mL rather than 0.5 mL vials, especially in
high throughput clinics because of greater vial sharing. In this
situation there is no advantage to stocking a mixture of vials (100%
of 1 mL vials is always most cost-effective), but should pricing
change (so that 1 mL and 0.5 mL vials differ in price), optimal
stocking strategies should be evaluated as a priority. For safety
reasons (potential for contamination) vial sharing is only possible
on the day of vaccine reconstitution, even though potency remains
high when properly stored [23]. Research into methods of
preserving rabies vaccines and preventing contamination could
therefore enable more economical use of vaccines, including
production in larger volume vials.
Despite policies to provide PEP free-of-charge, many bite
victims need to pay to promptly obtain PEP. In the light of this, a
switch to ID administration could reduce costs to bite victims. But,
there are many ways to charge for PEP. Only in high throughput
locations, where vials can be shared completely, could patients be
charged exactly for vaccine used without clinics operating at a loss.
Rates could be set proportional to clinic throughput to prevent
losses and ensure cost-recovery, but this would result in inequities
(with higher throughput clinics providing cheaper PEP) that would
disadvantage patients attending lower throughput clinics, i.e. the
rural poor. More equitably, patients could be charged set rates that
are much lower than for IM PEP (Table 5), whilst ensuring cost
recovery (Figure 3). Savings (see Table 4) from higher throughput
clinics could subsidize either lower throughput clinics that might
operate at a loss, or the poorest patients who are unable to afford
PEP (e.g. as part of a rolling fund or an insurance system) or even
other rabies control and prevention activities. Innovative financing
mechanisms could provide more affordable PEP and generate
potentially high returns from high throughput clinics, but effective
monitoring would be critical.
Health policy aims to reduce the burden of disease, but conflicts
inevitably arise between the individual interests of patients and the
population-level interests of healthcare providers. Choices about
which regimens are preferable depend upon whether indirect or
direct costs are a greater obstacle to bite victims. When PEP is
provided free-of-charge, the recently developed 1-week ID
regimen and the Zagreb IM are most advantageous for patients,
because they entail fewer clinic visits. But both have drawbacks as
the 1-week ID regimen is not yet approved by WHO and the
Zagreb regimen, which is approved by WHO, uses more vaccine.
If budgets and therefore vaccine supply are limited, the 4-site, if
eventually approved by WHO, and updated TRC ID regimens
are most preferable. Policies need to balance these issues to reduce
costs for bite victims and prevent shortages.
A further consideration in PEP delivery is how to promote
compliance and therefore improve the effectiveness of PEP. We
assume that affordability of PEP will improve compliance and
provision of PEP free-of-charge is therefore the ideal solution
(Figure 4). However, when charging for PEP, flat rates that are
more affordable than IM regimes (e.g. $15 for a full course or $20
for the first two visits, see Table 2) might incentivise compliance,
but would recuperate costs only when 1 mL vials are used.
Alternatively wider distribution of vaccine (even when charging for
PEP) could reduce indirect costs for bite-victims and improve
compliance. Staying in the vicinity of a clinic rather than travelling
back and forth for each scheduled vaccination might also be
cheaper for bite-victims, which would apply particularly for the 1-
week ID regimen (we do not currently explore such complexities
but data could inform model inputs for future analyses). Although
the 1-week ID uses more vaccine than other ID regimens, reduced
indirect costs could make it more affordable for bite-victims. This
may facilitate compliance and has the added benefit of earlier
complete protection reducing anxiety for bite-victims. In contrast,
for the 4-dose ID regimen, the last dose of vaccine is not
administered until day 90, which could reduce compliance in
comparison to other ID regimens. Further study is therefore
warranted to better quantify indirect costs of obtaining PEP and to
understand the major constraints to PEP access and compliance
for those most in need. Incomplete and late PEP is less effective in
preventing the onset of disease, but there are no data available to
quantitatively compare risks to full compliance (we were only able
to explore hypothetical changes in PEP effectiveness with poor
compliance). Contact tracing could potentially reveal more about
these issues, and longitudinal serology studies could provide a
useful proxy measure for immunogenicity that could be used to
inform PEP policy.
Despite being more economical, misperceptions about ID, the
lack of strong recommendations and a profusion of complex
schedules have deterred their widespread adoption. Yet our
analyses show that switching from IM to ID administered PEP has
benefits to patients and healthcare providers. The updated TRC is
the only currently WHO approved ID regimen, but the 4-site ID
regimen is also highly cost-effective and the 1-week ID has other
benefits for bite-victims. Their further evaluation by WHO is
clearly warranted. More generally, since ID procedures involve
delivery of only small amounts of vaccine, in order to apply our
findings to settings where non pre-qualified vaccines are used,
rigorous evaluation of the product including manufacturing
standards, safety, immunogenicity and efficacy must be prioritized.
The absolute cost-effectiveness of PEP depends upon the
regimen, clinic throughput, clinic overhead and costs of materials
for vaccine delivery and vaccine vials. Nonetheless, our estimates
suggest that PEP is more cost-effective in averting deaths than
childhood immunization through the Expanded Program on
Immunization (USD$205/death averted in sub-Saharan Africa
and South Asia [24]), which is considered one of the most cost-
effective health interventions available [25]. Even considering
vaccine waste, the worst-case scenario for PEP cost-effectiveness is
around $200/death averted (for IM regimens) and in high
throughput clinics use of ID regimens can reduce costs to just
$60/death averted. Cost-effectiveness will decline if PEP is
administered to patients who are bitten by non-rabid animals.
We do not currently factor this into our calculations, but positive
predictive values obtained from field data in Cambodia and in
Tanzania [4,26] suggest that PEP is largely administered to
genuine rabid bite victims and that cost-effectiveness will remain
high even with liberal provision of PEP [19]. Thus effective PEP
delivery should be considered an extremely cost-effective invest-
ment for public health, given the current poor availability of this
life saving intervention. However, rabies can only be eliminated
through intervention in the animal reservoir [27], and this is likely
Cost-Effective Rabies Post-Exposure Vaccination
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in the long-term [28].
Our model has several simplifications, which could be
elaborated on in future. We assume that the day of the week
does not affect the likelihood of presenting for PEP vaccination.
But patients may be less likely to present on Sundays (in many
countries clinics providing PEP are not open on Sundays) and/or
more likely to present on Mondays or other days of the week (e.g.
after pay day), which may affect vial sharing. We also do not
include pre-exposure vaccination. Livestock officers and extension
workers involved in animal vaccinations and more at risk of animal
bites should be pre-vaccinated. Pre-exposure vaccinations would
likely make PEP more cost-effective (as less vaccine is required in
the event of an exposure) and preliminary vaccinations could be
coordinated to ensure effective vial sharing (e.g. prior to dog
vaccination campaigns). But, in general in low-income countries,
such pre-vaccinated persons are rare relative to non-vaccinated
bite victims. In some high-risk settings pre-vaccination of children
is under consideration [29], and our simulation framework could
be useful for their further evaluation.
The availability and affordability of PEP is critical in
determining the burden of rabies. Incidence in resource poor
countries is directly affected by the inability of bite victims to
obtain PEP and obtain it promptly. Reducing the cost of PEP and
preventing administration delays is therefore particularly impor-
tant in resource-limited settings. The variety of PEP regimens, vial
sizes, and routes of administration has also made the delivery of
these life-saving vaccines unnecessarily complicated. Our results
provide evidence to show that a simplification to universal ID
delivery of PEP could have massive advantages in low-income
countries: streamlining guidelines, reducing the volume of vaccine
use, mitigating vaccine shortages and making PEP more affordable
to the most vulnerable. Health workers routinely deliver childhood
immunizations intradermally, so there should be no technical
difficulty in switching to ID administration. ID vaccination is as
safe and efficacious as IM vaccination and is well-tolerated [30].
The immense advantages of ID PEP delivery should be specifically
highlighted in outbreak situations, such as those recently reported
from Bali [31] and in areas where vaccine supply is limited, as
considerably more bite victims can be protected using the same
volume of vaccine.
Supporting Information
Figure S1 Cost of vaccination per rabies death averted (life
saved) for different PEP regimens according to clinic throughput
and assuming imperfect vaccine use (460.1 mL injections from a
0.5 mL vial, and 860.1 mL injections from a 1 mL vial). Costs for
IM administered vaccinations (the Zagreb regimen and the Essen
4-dose reduced regimen are exactly equivalent and shown in
black) and ID administered vaccinations (the updated TRC
regimen is shown in blue, the 4-site in red, and the 1-week in grey)
per rabies death averted is plotted against clinic throughput (the
number of new animal bite patients presenting for PEP
vaccination each month). Shading represents 99% confidence
intervals resulting from variation in patient arrival dates and the
effects on vial sharing. Dashed lines highlight optimal vaccine use
in high throughput clinics. Panel A is based on 0.5 mL vials and
panel B on 1 mL vials. Note the x-axis is plotted on a log scale.
Found at: doi:10.1371/journal.pntd.0000982.s001 (0.03 MB PS)
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